{
    "clinical_study": {
        "@rank": "67166", 
        "arm_group": [
            {
                "arm_group_label": "Betaine", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Betaine is important in cellular metabolic pathways.  Few epidemiologic studies link betaine\n      levels to diabetes and cardiovascular disease.  Small human studies suggest benefit for\n      non-alcoholic liver disease.  In this study we will determine if administration of betaine\n      improves metabolic measures, liver fat and/or endothelial function in humans with glucose\n      intolerance who are overweight."
        }, 
        "brief_title": "Metabolic Effects of Betaine Supplementation", 
        "condition": [
            "Obesity", 
            "Dysglycemia"
        ], 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "detailed_description": {
            "textblock": "This study is a single site, prospective, randomized (1:1), double masked, placebo\n      controlled trial to assess metabolic effects of betaine compared to placebo on glycemia and\n      insulin sensitivity, liver fat and endothelial function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1) Men and women aged 21-65 years old;\n\n          -  2) Dysglycemia/prediabetes is defined as impaired fasting glucose (\u2265100 mg/dl),\n             impaired glucose tolerance (2 hour post 75 g oral glucose load 140-200 mg/dl) or\n             HbA1c 5.7-6.5%);\n\n          -  3) Grade 1 obesity (BMI 27 to 36 kg/m2).\n\n        Exclusion Criteria:\n\n          -  1) cystathionine beta-synthase (CBS deficiency);\n\n          -  2) Presence of liver disease other than NAFLD;\n\n          -  3) Use of medications causing steatosis;\n\n          -  4) Known alcohol consumption \u2265 2 drink per day;\n\n          -  5) Use of medications known to cause insulin resistance;\n\n          -  6) Use of weight loss drugs (or program) within 3 months of screening;\n\n          -  7) Treatment with any experimental drug within the past 6 months;\n\n          -  8) Subjects must be willing to abstain from use of phosphodiesterase type 5 (PDE-5)\n             inhibitors;\n\n          -  9) Pregnancy or lactation, and women of child bearing potential must use adequate\n             contraception;\n\n          -  10) Surgery within 30 days of screening;\n\n          -  11) Heart disease defined as New York Heart Association Class III or IV cardiac\n             status or hospitalization for congestive heart failure, unstable angina, myocardial\n             infarction, cerebrovascular accident, transient ischemic attack or any\n             revascularization within 6 months;\n\n          -  12) Uncontrolled hypertension;\n\n          -  13) eGFR <60; 14) History of acquired immune deficiency syndrome;\n\n          -  15) History of malignancy within 5 years;\n\n          -  16) Hemoglobin <12 g/dL (males), <10 g/dL (females);\n\n          -  17) Triglycerides (TG) >500 mg/dL;\n\n          -  18) Poor mental function or any other reason to expect patient difficulty in\n             complying with study requirements;\n\n          -  19) Metal clips or implants that preclude magnetic resonance imaging."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01950039", 
            "org_study_id": "2013P001265", 
            "secondary_id": "7-13-CE-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Betaine", 
                "description": "Betaine or placebo administered orally in divided doses over 3 months.", 
                "intervention_name": "Betaine", 
                "intervention_type": "Drug", 
                "other_name": "trimethyl glycine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo administered orally in divided doses over 3 months", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Betaine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Obesity", 
            "Glucose Intolerance"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "allison.goldfine@joslin.harvard.edu", 
                "last_name": "Allison B. Goldfine, MD", 
                "phone": "617-309-2643"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02215"
                }, 
                "name": "Joslin Diabetes Center and Brigham and Womens Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Bedside to Bench and Back: Cardiometabolic Effects of Betaine Supplementation", 
        "overall_contact": {
            "email": "allison.goldfine@joslin.harvard.edu", 
            "last_name": "Allison B. Goldfine, MD", 
            "phone": "617-309-2643"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Partners Health Care Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Glucose tolerance test", 
                "measure": "Glucose tolerance", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Magnetic resonance imaging", 
                "measure": "Hepatic fat", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Brachial artery reactivity", 
                "measure": "Endothelial Function", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }, 
            {
                "description": "Euglycemic hyperinsulinemic clamp", 
                "measure": "Insulin sensitivity", 
                "safety_issue": "No", 
                "time_frame": "3 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01950039"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Joslin Diabetes Center", 
        "sponsors": {
            "collaborator": {
                "agency": "American Diabetes Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Joslin Diabetes Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}